Portola Pharmaceuticals Inc., of South San Francisco, Calif., reported safety and efficacy data from a Phase II proof-of-concept study of PRT4445 of Eliquis (apixaban) in healthy volunteers

Oxigene Inc., of South San Francisco, completed enrollment of 110 patients in a Phase II trial of the antiangiogenic therapeutic Zybrestat (fosbretabulin) plus bevacizumab (Avastin, Genentech Inc.) to treat advanced ovarian cancer

Cytokinetics Inc., of South San Francisco, initiated a Phase I trial of CK-2127107 in healthy male volunteers

Tobira Therapeutics Inc., of South San Francisco, reported results from a Phase IIb trial of cenicriviroc, a once-daily dual CCR5/CCR2 inhibitor, at the Conference on Retroviruses and Opportunistic Infections in Atlanta

KaloBios Pharmaceuticals Inc., of South San Francisco, said data from its Phase I/II study of KB002 (precursor chimeric anti-GM-CSF monoclonal antibody to KB003) in persistent asthma demonstrated preliminary safety, tolerability and signs of activity and support continued development of Humaneered antibody KB003

Genentech Inc., of South San Francisco, a member of the Roche Group, and Novartis AG, of Basel, Switzerland, said results from a Phase III trial, ASTERIA II, demonstrated that omalizumab met its primary endpoint in patients with moderate to severe chronic idiopathic urticaria, who remained symptomatic despite treatment with approved H1 antihistamine doses

Onyx Pharmaceuticals Inc., of South San Francisco, said Leukemia published results from the Phase II study known as PX-171-005, testing Kyprolis (carfilzomib) in patients with relapsed and refractory multiple myeloma and varying degrees of renal insufficiency

Portola Pharmaceuticals Inc., of South San Francisco, inked a clinical collaboration with Janssen Pharmaceuticals Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, and Bayer AG, of Leverkusen, Germany, to evaluate the safety of PRT4445, an antidote for Factor Xa inhibitors, in healthy volunteers to have been administered oral anticoagulant Xarelto (rivaroxaban

VistaGen Therapeutics Inc., of South San Francisco, said it completed its final Phase I study of AV-101, an oral prodrug candidate in development for multiple conditions involving chronic neuropathic pain

Exelixis Inc., of South San Francisco, said in an SEC filing that it received notice from Genentech Inc., also of South San Francisco, that the first patient was dosed in a pivotal Phase III trial testing BRAF inhibitor Zelboraf (vemurafenib) alone and in combination with GDC-0973 (XL518, RG7421) in previously untreated patients with malignant melanoma and the BRAF V600 mutation

KaloBios Pharmaceuticals Inc., of South San Francisco, said it started dosing in a Phase II study testing KB001-A, its anti-PcrV Humaneered pegylated monoclonal antibody fragment, in chronic Pseudomonas aeruginosa infection in cystic fibrosis patients

Achillion Pharmaceuticals Inc., of New Haven, Conn., said it completed enrollment in a pilot Phase IIa trial evaluating ACH-3102, a second-generation pan-genotypic NS5A inhibitor, in combination with ribavirin in patients with chronic genotype 1b hepatitis C virus (HCV) infection. The initial cohort enrolled eight patients to receive 12 weeks of combination treatment. To date, five patients have completed four weeks of treatment, and ACH-3102 has been well tolerated, with no serious adverse

Onyx Pharmaceuticals Inc., of South San Francisco, and Bayer AG, of Leverkusen, Germany, reported that a Phase III trial of Nexavar (sorafenib) in locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer met its primary endpoint of a statistically significant improvement of progression-free survival

Portola Pharmaceuticals Inc., of South San Francisco, said it started a Phase II study testing the safety and effectiveness of PRT4445, its universal antidote for Factor Xa inhibitor anticoagulants, in healthy volunteers who have been given approved and investigational Factor Xa inhibitors, including the oral drug Eliquis (apixaban, Bristol-Myers Squibb Co. and Pfizer Inc.) and Portola's own betrixaban

Theravance Inc., of South San Francisco, said it started a Phase II study testing TD-9855, its lead monoamine reuptake inhibitor program, in patients with fibromyalgia

Cytokinetics Inc., of South San Francisco, opened enrollment of the third and final cohort in its ATOMIC-AHF Phase IIb trial of omecamtiv mecarbil in left ventricular systolic dysfunction in patients hospitalized for heart failure

Talon Therapeutics Inc., of South San Francisco, said complete data from its Phase II RALLY study of Marqibo, a spingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate, were published in the Journal of Clinical Oncology

Genentech Inc., of South San Francisco, a member of the Roche Group, reported results from the Phase III AVAglio study showing that Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy improved progression-free survival by 36 percent vs

Threshold Pharmaceuticals Inc., of South San Francisco, gave an update on its results from a Phase II trial of TH-302 in soft-tissue sarcoma, with additional results from patients who received it as a maintenance therapy after induction with TH-302 and doxorubicin